Search results for "Dose"

showing 10 items of 2247 documents

Raloxifene promotes prostacyclin release in human endothelial cells through a mechanism that involves cyclooxygenase-1 and -2

2005

Objective To examine the effects of raloxifene on prostacyclin production by human umbilical vein endothelial cells (HUVEC) and to shed light on the molecular details of that action. Design Cell culture for 4, 8, 16, 24, and 48 hours. Setting University research laboratory. Patient(s) Source of HUVEC. Intervention(s) Measurement of prostacyclin production and of protein levels and mRNA expression of cyclooxygenase (COX)-1 and -2. Main Outcome Measure(s) Prostacyclin production was measured by enzyme immunoassay, the mRNA expression of COX-1 was measured by quantitative real time-polymerase chain reaction, and the protein levels of COX-1 and -2 were measured by immunoblotting. Result(s) Ralo…

medicine.medical_specialtyEndotheliumAgonist-antagonistEstrogen receptorProstacyclinPharmacologyGene Expression Regulation EnzymologicUmbilical veinInternal medicinemedicineHumansCyclooxygenase InhibitorsRaloxifeneCells CulturedDose-Response Relationship DrugbiologyChemistryEndothelial CellsObstetrics and GynecologyEpoprostenolEndothelial stem cellmedicine.anatomical_structureEndocrinologyReproductive MedicineCyclooxygenase 2Raloxifene HydrochlorideCyclooxygenase 1biology.proteinCyclooxygenasemedicine.drugFertility and Sterility
researchProduct

Characteristics of histamine tachyphylaxis in rat uterine smooth muscle.

2002

Objective and design: To study both the desensitisation induced by short-term exposure to histamine and the mechanism responsible in the isolated rat uterus.¶Material: Precontracted isolated uterus (37 mM KCl) from oestrogenised Wistar rats were used.¶Treatment: Repetitive responses to histamine (10–6, 10–5, 10–4, 10–3 M), dimaprit and clonidine (10–4 M) were tested at 15, 30, 45 and 105 min., with their modifications by (5 mg/ kg, 24 h before sacrifice) reserpine, 10–7 M propranolol, 10–8 M atropine, and 10–6 M indomethacin. Dose-response curves for adrenaline were carried out as standard protocol.¶Methods: In vitro techniques (de Jalon's solution, 31°C, carbogen, isotonic registration, re…

medicine.medical_specialtyEpinephrineMuscle RelaxationImmunologyPropranololTachyphylaxisIn Vitro TechniquesClonidineHistamine Agonistschemistry.chemical_compoundUterine ContractionDimapritInternal medicinemedicineCyclic AMPAnimalsIsotonic ContractionRats WistarTachyphylaxisPharmacologyDose-Response Relationship Drugbusiness.industryUterusEstrogensReserpineDimapritClonidineRatsAtropineDose–response relationshipEndocrinologychemistryFemalebusinessAdrenergic alpha-AgonistsHistaminemedicine.drugHistamineInflammation research : official journal of the European Histamine Research Society ... [et al.]
researchProduct

Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia

2018

Background: Intravenous immunoglobulin (IVIG) IQYMUNE® is a highly purified 10% IVIG that was assessed using the new stringent definition of response described in the revised guideline on the clinical investigation of IVIG. The efficacy and the safety of IQYMUNE® were investigated in adult patients with chronic primary immune thrombocytopenia (ITP). Methods: In this phase III multinational, multicentre, prospective, uncontrolled, open-label, single-arm study, adult patients with a baseline platelet count < 30 × 10 9 /L were treated with IVIG 10% at a dose of 2 g/kg body weight administered over 2 consecutive days. The primary endpoint was Response over the study period and was defined accor…

medicine.medical_specialtyEuropean Medicines Agency guidelinesPlatelet countRenal functionHigh dose030204 cardiovascular system & hematologyGastroenterology03 medical and health sciencesIntravenous immunoglobulin; High dose; Immune thrombocytopenia; Response; European Medicines Agency guidelines; Platelet count; Bleeding assessment; Infusion rate0302 clinical medicineInfusion rateInternal medicinemedicineClinical endpointPlateletAdverse effectIntravenous immunoglobulinbiologybusiness.industryResponseGuidelineImmune thrombocytopeniaImmune thrombocytopenia030220 oncology & carcinogenesisConcomitantbiology.proteinBleeding assessmentOriginal ArticleAntibodybusinessJournal of Hematology
researchProduct

1712 Serum Electrolytes Variations in Treated Patients with Moderate Asthma Exacerbation

2012

Background Salbutamol induces stimulation of beta 2 -receptors resulting in hypokalemia. Corticosteroids also induce plasma electrolytes variations. Aims To identify blood electrolytes changes following low dose inhaled short-acting beta 2 -agonists; To evaluate if concomitant inhaled corticosteroids treatment can amplify serum electrolytes changes. Methods We analyzed all children admitted for moderate asthma exacerbation during 6 months period. Inclusion criteria: children between 5–18 years of age; PEF >50–75% of predicted value; serum electrolytes normal ranges. Exclusion criteria: previously treated patients with Salbutamol; Salbutamol hypersensitivity; asthma exacerbation severity lev…

medicine.medical_specialtyExacerbationbusiness.industryModerate asthmaGastroenterologyMetered-dose inhalerHypokalemiaInternal medicineConcomitantAnesthesiaPediatrics Perinatology and Child HealthmedicineSalbutamolSerum electrolytesmedicine.symptombusinessBeta (finance)medicine.drugArchives of Disease in Childhood
researchProduct

Inhibition of intracellular Ca2+ release by a Rho-kinase inhibitor for the treatment of ischemic damage in primary cultured rat hippocampal neurons.

2008

The effects of hydroxy fasudil, a specific Rho-kinase inhibitor, on behavior and brain neuronal activity in animal studies have been described previously. However, whether a Rho-kinase inhibitor can directly protect neurons against ischemic damage and the molecular mechanisms underlying these effects are poorly understood. The present work was designed to investigate the effect of hydroxy fasudil against oxygen-glucose deprivation (OGD) induced acute neuronal injury and the underlying mechanisms in vitro. Pretreatment with hydroxy fasudil at 5 and 10 microM could concentration-dependently improve cell viability and decrease Lactate dehydrogenase (LDH) level in extracellular solution of neur…

medicine.medical_specialtyExcitotoxicityIntracellular SpaceGlutamic AcidBiologymedicine.disease_causeNeuroprotectionHippocampusCalcium in biologyPotassium ChlorideRats Sprague-DawleyCalcium imagingAdenosine TriphosphateIschemiaInternal medicine1-(5-Isoquinolinesulfonyl)-2-MethylpiperazinemedicineAnimalsHypoxiaProtein Kinase InhibitorsCells CulturedPharmacologyNeuronsrho-Associated KinasesDose-Response Relationship DrugCalcium channelFasudilGlutamate receptorRatsEndocrinologyGlucoseRho kinase inhibitorCalciumEuropean journal of pharmacology
researchProduct

Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia.

2007

In order to assess the long-term (12 months) efficacy and safety of fenofibrate administered with simvastatin in the treatment of primary mixed hyperlipidaemia, we conducted a study that compared increasing dosages of these drugs in subgroups of men and women belonging to a clinical sample of outpatients. This was an open study carried out in patients with primary mixed hyperlipidaemia (lipoprotein phenotype IIb) who needed a combined therapeutic approach because of their poor response to a single-drug regimen with an HMG-CoA reductase inhibitor (simvastatin). Thus, a fibrate (fenofibrate) was added to the therapy. The study lasted 12 months. Forty-five patients (mean age: 58.9 ± 11.3 years…

medicine.medical_specialtyFenofibrateDosemedicine.drug_classbusiness.industrynutritional and metabolic diseasesGeneral MedicineFibratePharmacologyGastroenterologyDiscontinuationRegimenTolerabilitySimvastatinInternal medicinemedicinelipids (amino acids peptides and proteins)Pharmacology (medical)Adverse effectbusinessmedicine.drugClinical drug investigation
researchProduct

Progression criteria in loading exercise programmes in lower limb tendinopathy: a protocol for a systematic review and meta-analysis

2019

IntroductionLower limb tendinopathies have high rates of incidence and prevalence. Their symptomatology affects the functional capacity of people to exercise and work, being an important cause of economic and social burden. The evidence from the last decades points to therapeutic exercise as the first-line treatment in tendinopathies due to its good short-term and long-term clinical outcomes. However, there is no consensus about how the load progression should be managed throughout the therapeutic exercise programmes.Methods and analysisThis systematic review will be conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The present p…

medicine.medical_specialtyFisioteràpiaPsychological interventionScopusexercise prescriptionPhysical exerciseLower limbRehabilitation Medicine03 medical and health sciences0302 clinical medicineMeta-Analysis as Topicsystematic reviewProtocolHumansMedicine1506patellar tendinopathy030212 general & internal medicine1727Pain Measurementgluteal tendinopathyExercise ToleranceAchilles tendinopathybusiness.industrydoseGeneral MedicinePhysical Functional Performancemedicine.diseaseExercise TherapySystematic reviewLower ExtremityResearch DesignMeta-analysisTendinopathyPhysical therapyTendinopathybusinessExercise prescription030217 neurology & neurosurgerySystematic Reviews as Topic
researchProduct

Cloning of two melanocortin (MC) receptors in spiny dogfish

2004

We report the cloning and characterization of two melanocortin receptors (MCRs) from the spiny dogfish (Squalus acanthias) (Sac). Phylogenetic analysis shows that these shark receptors are orthologues of the MC3R and MC5R subtypes, sharing 65% and 70% overall amino acid identity with the human counterparts, respectively. The SacMC3R was expressed and pharmacologically characterized in HEK293 cells. The radioligand binding results show that this receptor has high affinity for adrenocorticotropic hormone (ACTH)-derived peptides while it has comparable affinity for alpha- and beta-melanocyte stimulating hormone (MSH), and slightly lower affinity for gamma-MSH when compared with the human ortho…

medicine.medical_specialtyGreen Fluorescent ProteinsMolecular Sequence DataCHO CellsAdrenocorticotropic hormoneBiologyPolymerase Chain ReactionBiochemistryCell LineRadioligand Assaygamma-MSHAdrenocorticotropic HormoneCricetinaeInternal medicineCyclic AMPEscherichia colimedicineAnimalsHumansPotencyBacteriophagesTissue DistributionAmino Acid SequenceMelanocyte-Stimulating HormonesCloning MolecularReceptorPhylogenyGene Librarychemistry.chemical_classificationSpiny dogfishDose-Response Relationship DrugSequence Homology Amino AcidReverse Transcriptase Polymerase Chain ReactionChinese hamster ovary cellHEK 293 cellsSequence Analysis DNAbiology.organism_classificationMolecular biologyIntronsAmino acidBlotting SouthernKineticsEndocrinologychemistryDogfishReceptor Melanocortin Type 4MelanocortinPeptidesReceptor Melanocortin Type 3European Journal of Biochemistry
researchProduct

A human hepatocellular in vitro model to investigate steatosis

2006

The present study was designed to define an experimental model of hepatocellular steatosis with a fat overaccumulation profile in which the metabolic and cytotoxic/apoptotic effects could be separated. This was accomplished by defining the experimental conditions of lipid exposure that lead to significant intracellular fat accumulation in the absence of overt cytotoxicity, therefore allowing to differentiate between cytotoxic and apoptotic effects. Palmitic (C16:0) and oleic (Cl 8: 1) acids are the most abundant fatty acids (FFAs) in liver triglycerides in both normal subjects and patients with nonalcoholic fatty liver disease (NAFLD). Therefore, human hepatocytes and HepG2 cells were incub…

medicine.medical_specialtyHepG2Carcinoma HepatocellularCell SurvivalPalmitic AcidApoptosisBiologyFatty Acids NonesterifiedIn Vitro TechniquesToxicologyfatty acidscellular steatosisPalmitic acidchemistry.chemical_compoundInternal medicineCell Line TumorNonalcoholic fatty liver diseasemedicineHumansCytotoxicityDose-Response Relationship DrugapoptosisGeneral Medicinemedicine.diseaseFatty LiverDose–response relationshipmedicine.anatomical_structureEndocrinologychemistryBiochemistryApoptosisNeutral RedHepatocyteHepatocyteslipids (amino acids peptides and proteins)hepatocytesSteatosisIntracellularOleic Acid
researchProduct

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

2005

Background/Aims: Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy. Methods: Retrospective analysis of data from 1121 adults with chronic hepatitis C treated for 48 weeks with peginterferon alfa-2a (40 KD) 180 mu g/week plus placebo or ribavirin (1000/1200 mg/day), or interferon alfa-2b 3 MIU three times/week plus ribavirin in a randomized, multinational, study. Results: 67% of patients treated with peginterferon alfa-2a (40 KD)/ribavirin with early virological responses (HCV RNA negative or >= 2 log(10) decrease) at week 12 had SVRs at week 72 (HCV RNA 80 % of the planned ribavirin dose. Concl…

medicine.medical_specialtyHepatitis B virusviral hepatitisAlpha interferonPeginterferon-alfaInterferon alpha-2medicine.disease_causeGastroenterologyAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundpredictabilityInternal medicineRibavirinmedicinechronic hepatitis CHumansProbabilityRetrospective StudiesHepatitis B viruspeginterferon alfa-2a (40 KD)treatmentHepatologyDose-Response Relationship Drugbusiness.industryRibavirinvirus diseasesInterferon-alphaHepatitis CHepatitis C ChronicViral Loadmedicine.diseasedigestive system diseasesRecombinant ProteinsTreatment OutcomechemistryImmunologyRNA ViralDrug Therapy Combinationsustained virological responseViral hepatitisbusinessViral loadPeginterferon alfa-2amedicine.drugJournal of hepatology
researchProduct